To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.
HIV infection confirmed.
Receiving cART more than 12 months.
HIV viral-load < 50 copies/ml and CD4 cell count more than 350 cells/ul.
Without serious liver, heart, liver and kidney diseases.
With active HBV or HCV infection, or serious opportunistic infections.
With serious chronic disease such like diabetes, the mental illness,et al
History of suffering from pancreatitis during cART.
Pregnant or breast-fed.
Guangzhou 8th People's Hospital
Lead sponsor
Sun Yat-sen University
Collaborator